A clinical briefing for providers on Arformoterol (Brovana) availability in 2026. Coverage of supply status, prescribing considerations, and patient access tools.
If your COPD patients on nebulized Arformoterol (Brovana) are reporting difficulty filling their prescriptions, you're not alone in hearing those concerns. While Arformoterol is not formally listed on the FDA's drug shortage database, real-world access challenges persist — driven by pharmacy stocking patterns, insurance barriers, and the medication's niche market position.
This briefing covers what you need to know as a prescriber: the current supply landscape, clinical implications, cost considerations, and tools to help your patients maintain access to their therapy.
Arformoterol Tartrate (Brovana) received FDA approval in 2006 as the first nebulized long-acting beta-2 agonist (LABA) for maintenance treatment of bronchoconstriction in COPD. Key milestones include:
Arformoterol occupies a specific clinical niche: it's one of only two nebulized LABAs available in the U.S. (alongside Formoterol/Perforomist). Your patients on this medication likely fall into one or more of these categories:
For patients who truly need nebulized LABA therapy, alternatives are limited to Perforomist (Formoterol Fumarate, 20 mcg twice daily via nebulizer). A comprehensive comparison is available in our patient-facing article on alternatives to Arformoterol.
Standard dosing: 15 mcg (one 2 mL vial) inhaled via jet nebulizer twice daily, morning and evening. Maximum: 30 mcg/day. Not for acute bronchospasm — patients should have a short-acting beta-agonist (SABA) rescue inhaler available.
The boxed warning regarding asthma-related death was removed from Brovana's labeling in May 2019. Current labeling retains warnings about:
For detailed interaction guidance, see our reference on Arformoterol drug interactions.
The disconnect between Arformoterol's manufacturing status and patient access comes down to several factors:
Most chain pharmacies manage inventory algorithmically based on dispensing volume. Arformoterol's relatively low prescription volume means many locations don't carry it as standard stock. Independent and specialty pharmacies — particularly those serving pulmonary patient populations — are more likely to stock it or order it quickly.
Arformoterol remains available through major pharmaceutical wholesalers. Pharmacies that don't stock it can typically order it within 1–2 business days. The issue is often awareness — patients (and sometimes staff) may interpret "not in stock" as "unavailable" when it's actually orderable.
Availability varies significantly by region. Areas with larger elderly populations or more pulmonology practices tend to have better pharmacy coverage for nebulized medications.
Cost remains a significant barrier for many patients:
Many commercial plans require prior authorization or step therapy. Documenting clinical necessity for nebulized therapy — specifically the patient's inability to use handheld devices — can support prior authorization appeals.
No active manufacturer copay card program is currently available for Brovana or generic Arformoterol. Sunovion Pharmaceuticals offers a patient assistance program for eligible uninsured/underinsured patients through their direct application process. Additional resources include RxAssist.org and NeedyMeds.org.
A detailed cost guide for patients is available at how to help patients save money on Arformoterol.
Here are practical tools to help your patients access Arformoterol:
Medfinder allows providers to check real-time pharmacy availability for Arformoterol by location. You can direct patients to pharmacies with confirmed stock or integrate availability checks into your prescribing workflow.
When submitting prior authorization for nebulized Arformoterol, include:
Consider maintaining a short list of local pharmacies that reliably stock nebulizer medications. Independent pharmacies and specialty respiratory pharmacies are often the most consistent sources for Arformoterol.
Several trends may improve Arformoterol access over the coming year:
Arformoterol remains an important therapeutic option for COPD patients who require nebulized LABA therapy. While not in formal shortage, the medication's limited distribution footprint creates real access challenges for patients. By understanding the availability landscape, leveraging tools like Medfinder for Providers, and proactively supporting prior authorization requests, you can help your patients maintain consistent access to this essential medication.
For additional provider resources, see our companion guide: how to help your patients find Arformoterol in stock.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
